These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

600 related items for PubMed ID: 10362349

  • 21. [Left-ventricular hypertrophy as a cardiac risk factor: role of the renin-angiotensin-aldosterone system].
    Erne P.
    Praxis (Bern 1994); 1996 Feb 20; 85(8):227-33. PubMed ID: 8701189
    [Abstract] [Full Text] [Related]

  • 22. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
    Aulakh GK, Sodhi RK, Singh M.
    Life Sci; 2007 Aug 02; 81(8):615-39. PubMed ID: 17692338
    [Abstract] [Full Text] [Related]

  • 23. [ACE-inhibitors, AT1 receptor antagonists and diastolic dysfunction].
    Metra M, Nodari S, Bordonali T, Cagnazzi E, Boldi E, Dei Cas L.
    Cardiologia; 1999 Dec 02; 44 Suppl 1(Pt 1):53-8. PubMed ID: 12497882
    [No Abstract] [Full Text] [Related]

  • 24. ACE inhibitor use in elderly patients with systolic left ventricular dysfunction: problems and opportunities.
    Pitt B.
    Br J Clin Pract Suppl; 1996 Jul 02; 84():11-6. PubMed ID: 8994996
    [Abstract] [Full Text] [Related]

  • 25. Exploring new treatment strategies in heart failure.
    Swedberg K.
    Blood Press Suppl; 2000 Jul 02; 1():44-8. PubMed ID: 11059637
    [Abstract] [Full Text] [Related]

  • 26. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE, Julius S.
    Am Heart J; 2004 Nov 02; 148(5):747-54. PubMed ID: 15523303
    [Abstract] [Full Text] [Related]

  • 27. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA, Molnar J, Arora RR.
    Diabetes Obes Metab; 2008 Jan 02; 10(1):41-52. PubMed ID: 18095949
    [Abstract] [Full Text] [Related]

  • 28. Angiotensin II receptor blockers in chronic heart failure--not as ELITE as expected!
    Farquharson CA, Struthers AD.
    J Renin Angiotensin Aldosterone Syst; 2000 Mar 02; 1(1):21-2. PubMed ID: 11967790
    [Abstract] [Full Text] [Related]

  • 29. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.
    Carson PE.
    Am Heart J; 2000 Sep 02; 140(3):361-6. PubMed ID: 10966531
    [Abstract] [Full Text] [Related]

  • 30. [Renin-angiotensin system modulation: instructions for use].
    Bellis A, Rozza F, Crispo S, Trimarco B.
    G Ital Cardiol (Rome); 2008 Feb 02; 9(2):79-89. PubMed ID: 18383770
    [Abstract] [Full Text] [Related]

  • 31. [Angiotensin II AT1 receptor antagonists: clinical development and future perspectives].
    Burnier M, Brunner HR.
    Therapie; 1998 Feb 02; 53(3):279-84. PubMed ID: 9773127
    [Abstract] [Full Text] [Related]

  • 32. Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction.
    Udelson JE, Konstam MA.
    J Card Fail; 2002 Dec 02; 8(6 Suppl):S465-71. PubMed ID: 12555159
    [Abstract] [Full Text] [Related]

  • 33. Effects of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on beta-adrenoceptor signaling in heart failure produced by myocardial Infarction in rabbits: reversal of altered expression of beta-adrenoceptor kinase and G i alpha.
    Makino T, Hattori Y, Matsuda N, Onozuka H, Sakuma I, Kitabatake A.
    J Pharmacol Exp Ther; 2003 Jan 02; 304(1):370-9. PubMed ID: 12490614
    [Abstract] [Full Text] [Related]

  • 34. Angiotensin II receptor blockade and ventricular remodelling.
    Anavekar NS, Solomon SD.
    J Renin Angiotensin Aldosterone Syst; 2005 Mar 02; 6(1):43-8. PubMed ID: 16088851
    [Abstract] [Full Text] [Related]

  • 35. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK, Duval S, Manske C, Vazquez G, Barber C, Miller L, Luepker RV.
    Am Heart J; 2007 Jun 02; 153(6):1064-73. PubMed ID: 17540211
    [Abstract] [Full Text] [Related]

  • 36. A hard look at angiotensin receptor blockers in heart failure.
    Gring CN, Francis GS.
    J Am Coll Cardiol; 2004 Nov 02; 44(9):1841-6. PubMed ID: 15519017
    [Abstract] [Full Text] [Related]

  • 37. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
    Weir R, McMurray JJ.
    Heart; 2005 May 02; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
    [Abstract] [Full Text] [Related]

  • 38. [New aspects of ACE inhibitor treatment of heart failure].
    Dietz R, Osterziel KJ.
    Z Kardiol; 1996 May 02; 85 Suppl 6():241-6. PubMed ID: 9064971
    [Abstract] [Full Text] [Related]

  • 39. Angiotensin blocking drugs and the heart beyond 2000.
    Morgan TO, Delbridge LM.
    J Am Soc Nephrol; 1999 Jan 02; 10 Suppl 11():S243-7. PubMed ID: 9892172
    [Abstract] [Full Text] [Related]

  • 40. Angiotensin II in the failing heart. Short communication.
    Schulz R, Heusch G.
    Kidney Blood Press Res; 2005 Jan 02; 28(5-6):349-52. PubMed ID: 16534230
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.